Letter to the editor: Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: Impact of the 79A>C cytidine deaminase polymorphism

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 959-960

  Mercier, Cédric ^a   Dahan, Laetitia ^a   Ouafik, L'Houcine ^b   André, Nicolas ^a   Ciccolini, Joseph ^b  

^a TIMONE HOSPITAL   (France)

^b North University Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; CYTIDINE DEAMINASE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

CANCER PATIENT; ENZYME POLYMORPHISM; EPIGENETICS; GENE MUTATION; GENOTYPE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SAMPLE SIZE;

ADENINE; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYTIDINE DEAMINASE; CYTOSINE; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN;

EID: 77956188531     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0859-5     Document Type: Letter

References (5)

1. Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DR, de Vries EG, Groen HJ (2010) Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol. doi: 10.1007/s00228-010-0799-0
2. J Ciccolini L Dahan N André A Evrard M Duluc A Blesius C Yang S Giacometti C Brunet C Raynal A Ortiz N Frances A Iliadis F Duffaud JF Seitz C Mercier 2010 Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies J Clin Oncol 28 160 165 10.1200/JCO.2009.24.4491 1:CAS:528:DC%2BC3cXhtF2rsrY%3D 19933910
3. HC Kirch J Schroder H Hoppe H Esche S Seeber J Schutte 1998 Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro Exp Hematol 26 421 425 1:CAS:528:DyaK1cXjtVSju7o%3D 9590659
4. JA Gilbert OE Salavaggione Y Ji, et al. 2006 Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics Clin Cancer Res 12 1794 1803 10.1158/1078-0432.CCR-05-1969 1:CAS:528:DC%2BD28Xis1CjsLo%3D 16551864
5. C Tibaldi E Giovannetti E Vasile V Mey A Laan S Nannizzi, et al. 2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 14 1797 1803 10.1158/1078-0432.CCR-07-1364 1:CAS:528: DC%2BD1cXjtleju78%3D 18347182